BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luke T, Bennett RS, Gerhardt DM, Burdette T, Postnikova E, Mazur S, Honko AN, Oberlander N, Byrum R, Ragland D, St Claire M, Janosko KB, Smith G, Glenn G, Hooper J, Dye J, Pal S, Bishop-Lilly KA, Hamilton T, Frey K, Bollinger L, Wada J, Wu H, Jiao JA, Olinger GG, Gunn B, Alter G, Khurana S, Hensley LE, Sullivan E, Jahrling PB. Fully Human Immunoglobulin G From Transchromosomic Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate. J Infect Dis 2018;218:S636-48. [PMID: 30010950 DOI: 10.1093/infdis/jiy377] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Lee HN, McWilliams IL, Lewkowicz AP, Engel K, Ireland DDC, Kelley-Baker L, Thacker S, Piccardo P, Manangeeswaran M, Verthelyi D. Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model. Emerg Microbes Infect 2021;10:2076-89. [PMID: 34674613 DOI: 10.1080/22221751.2021.1997075] [Reference Citation Analysis]
2 Fries L, Cho I, Krähling V, Fehling SK, Strecker T, Becker S, Hooper JW, Kwilas SA, Agrawal S, Wen J, Lewis M, Fix A, Thomas N, Flyer D, Smith G, Glenn G. Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults. J Infect Dis 2020;222:572-82. [PMID: 31603201 DOI: 10.1093/infdis/jiz518] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
3 Paskey AC, Frey KG, Schroth G, Gross S, Hamilton T, Bishop-Lilly KA. Enrichment post-library preparation enhances the sensitivity of high-throughput sequencing-based detection and characterization of viruses from complex samples. BMC Genomics 2019;20:155. [PMID: 30808306 DOI: 10.1186/s12864-019-5543-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
4 Gilliland T, Liu Y, Li R, Dunn M, Cottle E, Terada Y, Ryckman Z, Alcorn M, Vasilatos S, Lundy J, Larson D, Wu H, Luke T, Bausch C, Egland K, Sullivan E, Wang Z, Klimstra WB. Protection of human ACE2 transgenic Syrian hamsters from SARS CoV-2 variants by human polyclonal IgG from hyper-immunized transchromosomic bovines. bioRxiv 2021:2021. [PMID: 34341790 DOI: 10.1101/2021.07.26.453840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Cross RW, Speranza E, Borisevich V, Widen SG, Wood TG, Shim RS, Adams RD, Gerhardt DM, Bennett RS, Honko AN, Johnson JC, Hensley LE, Geisbert TW, Connor JH. Comparative Transcriptomics in Ebola Makona-Infected Ferrets, Nonhuman Primates, and Humans. J Infect Dis 2018;218:S486-95. [PMID: 30476250 DOI: 10.1093/infdis/jiy455] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
6 Ma B, Osborn M. Transgenic Animals for the Generation of Human Antibodies. In: Rüker F, Wozniak-knopp G, editors. Introduction to Antibody Engineering. Cham: Springer International Publishing; 2021. pp. 97-127. [DOI: 10.1007/978-3-030-54630-4_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 [DOI: 10.1101/2021.02.06.430072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Gunn BM, Bai S. Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection. Hum Vaccin Immunother 2021;:1-17. [PMID: 34613865 DOI: 10.1080/21645515.2021.1976580] [Reference Citation Analysis]
9 Tshiani Mbaya O, Mukumbayi P, Mulangu S. Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection. Front Immunol 2021;12:721328. [PMID: 34526994 DOI: 10.3389/fimmu.2021.721328] [Reference Citation Analysis]
10 Wang H, Wong G, Zhu W, He S, Zhao Y, Yan F, Rahim MN, Bi Y, Zhang Z, Cheng K, Jin H, Cao Z, Zheng X, Gai W, Bai J, Chen W, Zou Y, Gao Y, Gao GF, Yang S, Xia X, Qiu X. Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease. J Virol 2019;93:e01548-18. [PMID: 30541860 DOI: 10.1128/JVI.01548-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
11 Kumar D, Gauthami S, Bayry J, Kaveri SV, Hegde NR. Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond. Monoclon Antib Immunodiagn Immunother 2021;40:36-49. [PMID: 33900819 DOI: 10.1089/mab.2021.0004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Liu Z, Wu H, Egland KA, Gilliland TC, Dunn MD, Luke TC, Sullivan EJ, Klimstra WB, Bausch CL, Whelan SPJ. Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants. Hum Vaccin Immunother 2021;:1-10. [PMID: 34228597 DOI: 10.1080/21645515.2021.1940652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]